Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Stage migration, changed treatment profile and survival impact in newly diagnosed oesophago-gastric cancer in Scotland during the COVID-19 pandemic: A national study

M. Baxter 1, K.S. Khan 1, L. Gali 1, C. Samuelson 2, L.R. Narramani 2, M. Al-Zubaidi 1, G. Bryant 1, H. Shareef 1, R. Petty 1, M. Forshaw 1

1Molecular and Clinical Oncology Department, Clinical Research Centre - Ninewells Hospital - NHS Tayside, Dundee, UK; 2Department of Upper GI Surgery, Glascow Royal Infirmary - NHS Greater Glasgow and Clyde, Glascow, UK; 3Clinical Oncology Specialty Trainee, Edinburgh Cancer Centre - SCAN, Edinburgh, UK; 4Clinical Oncology Department, Aberdeen Royal Infirmary, Aberdeen, UK; 5Department of Upper GI Surgery, University Hospital Wishaw, Wishaw, UK; 6Molecular and Clinical Oncology Department, Clinical Research Centre - Ninewells Hospital - NHS Tayside, Dundee, UK

Background: COVID-19 has significantly disrupted cancer care. This may have impacted on staging, management and survival as health services worldwide had to adapt. Responding to the pandemic, the United Kingdom (UK) government declared a national lockdown on 23rd March 2020. This national study investigated the effect of the national response on oesophago-gastric (OG) cancers in Scotland, including time from referral to gastroscopy, staging at presentation, multidisciplinary team (MDT) treatment outcomes and overall survival.

Methods: This was a retrospective cohort study. Consecutive new patients presenting in NHS Scotland to five regional OG cancer MDTs covering 93.2% of the Scottish population between October 2019 and September 2020 were identified. Electronic health records were reviewed. The study period was divided into pre- and post-lockdown, based on the first UK national lockdown.

Results: 931 patients with biopsy-proven OG cancer were identified; 499 (53.6%) pre- and 432 (46.4%) post-lockdown. Median age at diagnosis was 61 years (range 25-95) and 60% were male. There were 252 (27.1%) gastric and 679 (72.9%) oesophageal cancers. No clinically meaningful difference in median time to gastroscopy was observed post-lockdown (13 vs 15 days, p = 0.001); however, patients were more likely to present with higher stage disease (stage 4; 57.6% vs 49.3%). There was a significant shift to palliative intent treatment post-lockdown (76.2% vs 64.7%, p < 0.005). AEs (≥ 28%) attributed to sotiga: nausea, anorexia, fatigue, cytokine release syndrome (CRS), pyrexia, vomiting, abnormal LFTs, thrombocytopenia, diarrhea, and pruritus; major Grade 1-2. Grade ≥ 3 CRS was observed in 3 pts (3%). No pt withdrawals due to sotiga; no treatment-related deaths. 28 pts were evaluable for the primary endpoint (1 opted against surgery, 1 pt withdrew after PTx, 1 unrelated death, 1 surgery still pending). Path responses: 10 pCR (36%), 16 pPR (57%), 18 major path resp (< 10% residual tumor) (64%). 2 PD (7%), ORR 93%. pCR by histology: 7/23 AC (30%), 5/5 SC (60%). Post-treatment evaluations of clinical outcomes (including DFS, OS) and immune-based biomarkers are ongoing.

Conclusions: Sotiga combined with neoadjuvant chemoradiation for esophageal/GEJ cancers was generally well tolerated and achieved pCR rates in both AC and SCC that compare favorably to historical data and are promising for this treatment strategy. Additional evaluations of clinical outcomes (including DFS, OS) and immune-based biomarkers are ongoing.

Clinical trial identification: NCT03165994.

Legal entity responsible for the study: Apexigen, Inc.

Funding: Apexigen, Inc.

Disclosure: A.H. Ko: Financial Interests, Personal, Other, Member of Data Monitoring Committee: National Cancer Institute, Rockville, MD, USA; Member, Scientific Advisory Board: Immatics, Rockville, MD, USA; Member, Scientific Advisory Board: Apexigen; Financial Interests, Institutional, Invited Speaker, Local PI for clinical trial: (pancreatic cancer): Celgene, Rockville/Gentechent, Cancer Immunotherapy. M. Noel: Financial Interests, Personal, Advisory Role: Celgene, Taisho Pharma, Ipsen; Financial Interests, Personal, Invited Speaker: Celgene, Taisho Pharma, Daiichi Sankyo/AstraZeneca; Financial Interests, Institutional, Funding: Apexigen. J. Chao: Financial Interests, Personal, Advisory Role: Lilly, Bristol-Myers Squibb; Financial Interests, Personal, Stock/Shares: Merck Serono, Janssen, Roche, Amgen, Astellas; Financial Interests, Institutional, Research Grant: AstraZeneca; Non-Financial Interests, Institutional, Product Samples: Lilly. All other authors have declared no conflicts of interest.

And 42-49% of squamous cell carcinomas (SCC) and is associated with improved survival outcomes. Sotigalimab (sotiga) is a high affinity CD40 agonist capable of inducing and expanding anti-tumor immune responses by activating dendritic cells (DCs), T cells, NK cells, B cells, and M1 macrophages. This study examined the safety and efficacy of combining sotiga with neoadjuvant CRT in pts with esophageal/GEJ cancers.

Methods: Pts with resectable (T1-4, N0) or SCC of the esophagus/GEJ were randomized 1:1 into T1NO and cervical tumors were excluded. Study treatment: cabazitaxel (AUC 2)/paclitaxel (PTX) (50 mg/m2) weekly x 5 with radiation 5040 cGy plus up to 4 doses of sotiga 0.3mg/kg IV prior to Ivor-Lewis esophagectomy. Primary efficacy endpoint was pCR.

Results: 34 pts were enrolled (safety pop); Histology: 76% AC, 24% SCC; clinical stage: IIA/IIB: 68%/23%; location: GEJ 46%. AEs (> 20%) attributed to sotiga: nausea, anorexia, fatigue, cytokine release syndrome (CRS), pyrexia, vomiting, abnormal LFTs, thrombocytopenia, diarrhea, and pruritus; major Grade 1-2. Grade ≥ 3 CRS was observed in 3 pts (9%). No pt withdrawals due to sotiga; no treatment-related deaths. 28 pts were evaluable for the primary endpoint (1 opted against surgery, 1 pt withdrew after PTx, 1 unrelated death, 1 surgery still pending). Path responses: 10 pCR (36%), 16 pPR (57%), 18 major path resp (< 10% residual tumor) (64%). 2 PD (7%), ORR 93%. pCR by histology: 7/23 AC (30%), 5/5 SC (60%). Post-treatment evaluations of clinical outcomes (including DFS, OS) and immune-based biomarkers are ongoing.

Conclusions: Sotiga combined with neoadjuvant chemoradiation for esophageal/GEJ cancers was generally well tolerated and achieved pCR rates in both AC and SCC that compare favorably to historical data and are promising for this treatment strategy. Additional evaluations of clinical outcomes (including DFS, OS) and immune-based biomarkers are ongoing.

Clinical trial identification: NCT03165994.

Legal entity responsible for the study: Apexigen, Inc.

Funding: Apexigen, Inc.

Disclosure: A.H. Ko: Financial Interests, Personal, Other, Member of Data Monitoring Committee: National Cancer Institute, Rockville, MD, USA; Member, Scientific Advisory Board: Immatics, Rockville, MD, USA; Member, Scientific Advisory Board: Apexigen; Financial Interests, Institutional, Invited Speaker, Local PI for clinical trial: (pancreatic cancer): Celgene, Rockville/Gentechent, Cancer Immunotherapy. M. Noel: Financial Interests, Personal, Advisory Role: Celgene, Taisho Pharma, Ipsen; Financial Interests, Personal, Invited Speaker: Celgene, Taisho Pharma, Daiichi Sankyo/AstraZeneca; Financial Interests, Institutional, Funding: Apexigen. J. Chao: Financial Interests, Personal, Advisory Role: Lilly, Bristol-Myers Squibb; Financial Interests, Personal, Stock/Shares: Merck Serono, Janssen, Roche, Amgen, Astellas; Financial Interests, Institutional, Research Grant: AstraZeneca; Non-Financial Interests, Institutional, Product Samples: Lilly. All other authors have declared no conflicts of interest.

https://doi.org/10.1016/j.annonc.2022.07.1346